Pfizer: COVID-19 vaccine still 100% effective in adolescents after four months

A two-dose series of the Pfizer-BioNTech COVID-19 vaccine was 100% effective against COVID-19 in 12-15 year olds more than four months after the second dose in the companies’ phase 3 clinical trial, Pfizer and BioNTech announced yesterday. The adverse event profile was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose, the companies said. They plan to submit the updated data to the Food and Drug Administration, which in May expanded the vaccine’s emergency use authorization to include 12-15 year olds.